Sage Journals: Discover world-class research

Abstract

Aims:

To evaluate the medium and long-term results of abobotulinumtoxinA (aboBTX-A) injection treatment in the management of refractory overactive bladder (OAB) symptoms owing to idiopathic detrusor overactivity.

Methods:

Prospective data were collected from consecutive patients who underwent intravesical injection of 250 units of aboBTX-A under general anaesthetic for OAB symptoms that were refractory to antimuscarinic therapy. Overactive bladder symptom scores (OABSS), Likhart quality of life (QoL) indices and post-void residual volumes (PVR) were compared before and 6 weeks after treatment. The Wilcoxon Signed Ranks test was used to compare changes in OABSS, QoL and PVR from baseline scores.

Results:

Seventy-three patients received 93 aboBTX-A injection treatments over a 5-year period. Overall, OABSS and QoL improved by a mean of 3.7 + 4.17 (p<0.001) and 2.1 + 2.06 (p<0.001), respectively. An improvement in the combined OABSS and QoL scores of two or more points was observed following 68 (70.8%) procedures. De novo self-catheterisation was required following 16 procedures (16.8%) but was discontinued by 3 months in nine cases. In patients undergoing repeat injection treatment, the mean (+ SD) duration of symptomatic relief (until the resumption of antimuscarinic therapy) was 12.3 + 9.8 months, while the mean (+ SD) interval between injection treatments was 26.7 ± 14.3 months.

Conclusion:

AbobotulinumtoxinA injection treatment, employing a dose of 250 units per treatment, confers results that compare very favourably with those reported for onobotulinumtoxinA.

Keywords

AbobotulinumtoxinA patient reported outcomes overactive bladder

Get full access to this article

View all access options for this article.

References

Coyne

Sexton

Vats

. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011; 77: 1081–1087.

Irwin

Milsom

Hunskaar

. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306–1314.

Coyne

Sexton

Kopp

. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: Results from EpiLUTS. BJU Int 2011; 108(9): 1459–1471.

Ganz

Smalarz

Krupski

. Economic costs of overactive bladder in the United States. Urology 2010; 75(3): 526–532.

Abrams

Cardozo

Fall

. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 167–178.

Sexton

Notte

Maroulis

. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011; 65(5): 567–568.

Gopal

Haynes

Bellamy

. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008; 112: 1311–1331.

Barkin

. Overactive bladder. Can J Urol 2011; 18(Suppl 1): 8–13.

Athanasopoulos

Giannitsas

. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 2011; 820816.

10.

Sahai

Khan

Dasgupta

. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: Results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177: 2231–2236.

11.

Brubaker

Richter

Visco

. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180: 217–222.

12.

Flynn

Amundsen

Perevich

. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009; 181: 2608–2615.

13.

Tincello

Kenyon

Abrams

. Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012 [in press].

14.

Dowson

Watkins

Khan

. Repeated botulinum toxin type A injections for refractory overactive bladder: medium term outcomes, safety profile and discontinuation rates. Eur Urol 2012; 61: 834–839.

15.

Schäfer

Abrams

Liao

. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure-flow studies. Neurol Urodyn 2002; 21: 261–274.

16.

Homma

Yoshida

Seki

. Symptom assessment tool for overactive bladder syndrome – overactive bladder symptom score. Urology 2006; 68(2): 318–323.

17.

Harper

. Botulinum toxin A – when is a unit not a unit ? J Urol 2009; 181(1): 414.

18.

Dmochowski

Chapple

Nitti

. Eficacy and safety of onobotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184(6): 2416–2422.

19.

Schmid

DMS

Roy-Guggenbuehl

Werner

. The Zurich experiences including 6 years reults of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for overactive bladder refractory to anticholinergics. Eur Urol 2008; 7(3): 212.

20.

Khan

Kessler

Apostolidis

. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection. J Urol 2009; 181(4): 1773–1778.

21.

Manecksha

Cullen

Ahmad

. Prospective randomized controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 2012; 61: 928–935.

Patient reported outcomes of abobotulinumtoxinA injection treatment for idiopathic detrusor overactivity: a pragmatic approach to management in secondary care

Abstract

Aims:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References